These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 8386279)

  • 1. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
    Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
    J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat.
    Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB
    Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.
    Scala G; Ruocco MR; Ambrosino C; Mallardo M; Giordano V; Baldassarre F; Dragonetti E; Quinto I; Venuta S
    J Exp Med; 1994 Mar; 179(3):961-71. PubMed ID: 8113688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
    Beauparlant P; Kwon H; Clarke M; Lin R; Sonenberg N; Wainberg M; Hiscott J
    J Virol; 1996 Sep; 70(9):5777-85. PubMed ID: 8709193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAR and Sp1-independent transactivation of HIV long terminal repeat by the Tat protein in the presence of human cytomegalovirus IE1/IE2.
    Dal Monte P; Landini MP; Sinclair J; Virelizier JL; Michelson S
    AIDS; 1997 Mar; 11(3):297-303. PubMed ID: 9147420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transactivation of heterologous promoters by HIV-1 tat.
    Han P; Brown R; Barsoum J
    Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of a human herpesvirus 6 gene segment capable of transactivating the human immunodeficiency virus type 1 long terminal repeat in an Sp1 binding site-dependent manner.
    Wang J; Jones C; Norcross M; Bohnlein E; Razzaque A
    J Virol; 1994 Mar; 68(3):1706-13. PubMed ID: 8107231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.
    Chang LJ; McNulty E; Martin M
    J Virol; 1993 Feb; 67(2):743-52. PubMed ID: 8419644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
    Nilsson T; Sjöblom A; Masucci MG; Rymo L
    Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages.
    Murphy KM; Sweet MJ; Ross IL; Hume DA
    J Virol; 1993 Dec; 67(12):6956-64. PubMed ID: 8230418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Tat protein can transactivate a heterologous TATAA element independent of viral promoter sequences and the trans-activation response element.
    Roebuck KA; Rabbi MF; Kagnoff MF
    AIDS; 1997 Feb; 11(2):139-46. PubMed ID: 9030359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.
    Kashanchi F; Shibata R; Ross EK; Brady JN; Martin MA
    J Virol; 1994 May; 68(5):3298-307. PubMed ID: 8151790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat.
    Mallon R; Borkowski J; Albin R; Pepitoni S; Schwartz J; Kieff E
    J Virol; 1990 Dec; 64(12):6282-5. PubMed ID: 2173793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
    Sjöblom A; Nerstedt A; Jansson A; Rymo L
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2669-78. PubMed ID: 7595374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter.
    Gómez-Gonzalo M; Carretero M; Rullas J; Lara-Pezzi E; Aramburu J; Berkhout B; Alcamí J; López-Cabrera M
    J Biol Chem; 2001 Sep; 276(38):35435-43. PubMed ID: 11457829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of responsiveness of a nuclear factor-kappaB-regulated promoter to transactivation by human immunodeficiency virus 1 Tat in HeLa cells.
    Kelly GD; Morris CB; Offermann MK
    Virology; 1999 Oct; 263(1):128-38. PubMed ID: 10544088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.
    Subler MA; Martin DW; Deb S
    J Virol; 1994 Jan; 68(1):103-10. PubMed ID: 8254719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lymphoblastoid cell lines.
    Zhang RD; Guan M; Park Y; Tawadros R; Yang JY; Gold B; Wu B; Henderson EE
    AIDS Res Hum Retroviruses; 1997 Jan; 13(2):161-71. PubMed ID: 9007201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semen Exosomes Promote Transcriptional Silencing of HIV-1 by Disrupting NF-κB/Sp1/Tat Circuitry.
    Welch JL; Kaddour H; Schlievert PM; Stapleton JT; Okeoma CM
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30111566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter.
    Zimber-Strobl U; Kremmer E; Grässer F; Marschall G; Laux G; Bornkamm GW
    EMBO J; 1993 Jan; 12(1):167-75. PubMed ID: 8381349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.